A5032670437- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Psoriasis: Treatment and Pathogenesis
- Immunodeficiency and Autoimmune Disorders
- Salivary Gland Disorders and Functions
- Salivary Gland Tumors Diagnosis and Treatment
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Dermatologic Treatments and Research
- Inflammatory Myopathies and Dermatomyositis
- Atherosclerosis and Cardiovascular Diseases
- Soft tissue tumor case studies
- COVID-19 Clinical Research Studies
- Autoimmune and Inflammatory Disorders
- SARS-CoV-2 and COVID-19 Research
- Eosinophilic Esophagitis
- Gastrointestinal disorders and treatments
- Cancer and Skin Lesions
- Long-Term Effects of COVID-19
- Business and Economic Development
- Economic Issues in Ukraine
- Mycobacterium research and diagnosis
Hospital Universitario Puerta de Hierro Majadahonda
2018-2023
Hospital Universitario de Fuenlabrada
2023
Hospital Universitario Rey Juan Carlos
2023
Novosibirsk State University of Economics and Management
2022
Tofacitinib (TOF) is the first Janus kinase (JAK) inhibitor approved for psoriatic arthritis (PsA). It has shown efficacy in patients refractory to anti-tumor necrosis factor-α randomized controlled trials (RCTs). Our aim was assess and safety of TOF clinical practice.This an observational, open-label multicenter study PsA treated with due inefficacy or adverse events previous therapies. Outcome variables were efficacy, corticosteroid dose-sparing effect, retention rate, safety. A...
<h3>Background</h3> Upadacitinib (UPA) is an inhibitor of JAK kinases recently approved by EMA for the treatment psoriatic arthritis (PsA) in Europe (January 2021) <sup>[1]</sup> UPA has shown efficacy refractory patients to anti-TNF <sup>[2]</sup> <h3>Objectives</h3> <b>A</b>) assess and safety first cases Spain clinical practice. <b>B</b>) compare profile practice (CP) with trial (CT) PsA biologics <h3>Methods</h3> Study 101 CP treated Spain. The diagnosis was made using CASPAR criteria....
<h3>Background:</h3> Belimumab is a human IgG1l monoclonal antibody directed against BAFF, B lymphocyte survival factor. It indicated as adjuvant treatment in adult patients with active systemic lupus erythematosus (SLE), positive autoantibodies and high degree of activity the disease despite standard treatment. <h3>Objectives:</h3> This study aims to describe sample diagnosed SLE who received belimumab tertiary hospital. <h3>Methods:</h3> Retrospective longitudinal unicentric observational...
Background: Tofacitinib (TOFA) is the first JAKi approved for psoriatic arthritis (PsA) in Europe (July 2018). TOFA has shown efficacy refractory patients to anti-TNF Randomized Clinical Trials (RCT) ( Gladman D. NEJM 2017; 377: 1525-36 ). Objectives: To assess and safety of clinical practice (CP). compare profile CP with RCT Methods: Study 87 PsA treated TOFA; Results are expressed as percentage, mean±SD or median [IRQ]. Results: (28♀/59♂), mean age 52.8±11.4 years (Table 1). Pattern joint...
Целью исследования является определение значения субъектов малого предпринимательства в экономике России, выявить тенденции развития и проблемы. Проанализировать эффективность результативность мер государственной поддержки предпринимательства. В результате проведенного получены выводы, свидетельствующие о наличии потенциала среднего для вклада общие экономические показатели страны. Россия отстает от других стран по доле бизнеса ВВП Распределение МСП регионам характеризуется высокой степенью...
<h3>Background</h3> Incorporation of conventional synthetic (cs), biologic (b) and targeted (ts) disease-modifying drugs (DMARDs) has enriched the therapeutic arsenal, but at same time complicated decision-making process, since it requires considering not only profile each patient characteristics drug, also high cost many them diverse administrative limitations. <h3>Objectives</h3> To analyze way acting Spanish rheumatologists in different clinical situations order to understand process...
<h3>Background</h3> Belimumab (BLM) is a monoclonal antibody that inhibits B-lymphocyte stimulating factor (BlyS) approved as specific treatment for systemic lupus erythematosus (SLE) in 2011. We present the experience with BLM Spanish cohort more than 460 patients. <h3>Objectives</h3> To describe demographic characteristics, efficacy and safety of patients SLE population since its approval. <h3>Methods</h3> Descriptive, retrospective, multicenter study diagnosed according to EULAR/ACR 2019,...
<h3>Background</h3> First multicenter study in clinical practice SLE patients treated with BLM Spain. <h3>Methods</h3> Descriptive, retrospective, diagnosed according to EULAR/ACR 2019, SLICC and/or ACR 1997 diagnostic criteria. Data regarding were collected from medical records (2011–2022). Demographic features, efficacy, analytical variables, SLEDAI, renal involvement, steroid dose, administration routes and safety assessed. <h3>Results</h3> Baseline characteristics of are summarized table...
<h3>Background</h3> Many treatments for rheumatic diseases, especially the new ones such as anti-TNF or anti-IL6 therapies, are known to increase risk of tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. <h3>Objectives</h3> To determine incidence infections in patients rheumatology unit our hospital. <h3>Methods</h3> We retrospectively reviewed results microbiological studies detection mycobacteria requested Rheumatology service hospital from January 1, 2008 October 2017....
<h3>Background:</h3> Tofacitinib (TOFA) is the first inhibitor of JAK kinases with approval for treatment psoriatic arthritis (PsA) in Europe (July 2018)<sup>1</sup>. ToFA has shown efficacy refractory patients to anti-TNF<sup>2</sup>. <h3>Objectives:</h3> <b>A)</b> assess and safety TOFA cases Spain clinical practice. <b>B)</b> compare profile practice trial. <h3>Methods:</h3> Study 41 PsA treated Spain. The diagnosis was made using CASPAR criteria. Patients who received at least one dose...
<h3>Background:</h3> Gastric angiodysplasia and the typical "watermelon stomach" aspect is one of most characteristic vascular manifestations in systemic sclerosis (SS). These angiodysplasias can affect intestine ocasionally as well stomach. <h3>Objectives:</h3> Description a series 5 patients with presence intestinal (IA). <h3>Methods:</h3> Retrospective unicentric observational study tertiary hospital. Demographic data, comorbidities, disease, serological profile, concomitant treatments...
<h3>Background:</h3> The time of rheumatoid arthritis (RA) evolution until treatment begins is key to controlling the disease. Many studies have shown that a prolonged duration symptoms at onset associated with more severe course RA. from first DMARD prescription >12 weeks in Spain, because diagnostic delay due either patient-related factors (delay consultation), Primary Care Physician (PCP) citation/referral) or rheumatologist citation). <h3>Objectives:</h3> To evaluate usefulness...
Background: Fecal calprotectin (FC) is a biomarker of bowel inflammation widely spread in diagnosis and follow-up inflammatory disease (IBD). It classically estimated that 5% patients with axial spondyloarthritis (SpA) also have IBD; coexistence both conditions has definite impact clinical decisions. Proactive detection diseases should be advisable, though appropriate screening tools are still lacking. Objectives: To evaluate the usefulness FC for IBD diagnosed SpA no suggestive...
Nowadays, relations between states are developing in the context of globalization. The international community is exposed to various challenges and risks. goal institutions global economic governance these conditions ensuring stability world economy stimulating its growth. To develop an effective strategy, it necessary increase speed efficiency responding crisis situations. relevance study determined by complexity, contradictions dynamism system political relations. purpose research evaluate...
Background The classification system for Sjögren’s syndrome (SS) proposed by the American-European Consensus Group (AECG) and revised diagrams American College of Rheumatology (ACR) include an altered minor salivary gland biopsy (MSGB) or positive antiRo, among other findings. Thus, MSGB is a particularly important finding in patients with autoantibody-negative. A retrospective cohort study showed that result led to definitive diagnosis 80% 1 . Objectives To assess usefulness SS anti-SSA/SSB...
Background Upadacitinib (UPA) is an inhibitor of JAK kinases recently approved by EMA for the treatment psoriatic arthritis (PsA) in Europe (January 2021) 1. UPA has shown efficacy refractory patients to anti-TNF 2. Objectives A ) assess and safety first cases Spain clinical practice. B compare profile practice with trial PsA biologics 2 . Methods Study 39 treated Spain. The diagnosis was made using CASPAR criteria. Patients who received at least one dose were included. Results are expressed...
Background The development of targeted biologic (bDMARDs) and synthetic disease-modifying drugs (tsDMARDS) has made a substantial change in the control our patients, allowed an increasing number patients to achieve clinical remission. Objectives To gain understanding patients’ experiences starting treatment with b/tsDMARDs, explore their attitudes order improve doctor-patient relationship, adherence treatment, compliance, knowledge about experience using b/tsDMARDs. Methods A qualitative...
Background The EPISER study is the first Spanish epidemiological that has confirmed great burden of rheumatic diseases in general population: they consume a large quantity health resources (doctor visits, medical products) and imply high social impact terms work absenteeism. Rheumatic represent almost 30% Primary Care consultations Spain 1,2 . Electronic consultation could be an alternative response to increase this demand, both make early diagnosis derivation improve communication with...
Background: SARS-CoV-2 virus is a novel coronavirus that causes COVID-19 disease, which in its most severe form produces life-threatening atypical pneumonia and ARDS. Coronaviruses induce dysregulation of the immune system resulting cytokine storm syndrome with activation macrophage mediated mainly by IL-1 IL-6. Although there no specific treatment to date, researchers have explored approaches through targeting both IL-6 IL-1. Anakinra recombinant human receptor antagonist prevents IL-1β...